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Abstract—Biomedical implantable sensors transmitting a 
variety of physiological signals have been proven very useful in 
the management of chronic diseases. Currently, the vast majority 
of these in-body wireless sensors communicate in frequencies 
below 1 GHz. Although the radio propagation losses through 
biological tissues may be lower in such frequencies, e.g., the 
medical implant communication services (MICS) band of 402-405 
MHz, the maximal channel bandwidths allowed therein constrain 
the implantable devices to low data rate transmissions. Novel and 
more sophisticated wireless in-body sensors and actuators may 
require higher data rate communication interfaces. Therefore, 
the radio spectrum above 1 GHz for the use of wearable medical 
sensing applications should be considered for in-body 
applications too. Wider channel bandwidths and smaller antenna 
sizes may be obtained in frequency bands above 1 GHz at the 
expense of larger propagation losses. Therefore, in this paper we 
present a phantom-based radio propagation study for the 
frequency bands of 2360-2400 MHz, which has been set aside for 
wearable body area network (BAN) nodes, and the industrial, 
scientific, medical (ISM) band of 2400-2483.5 MHz. Three 
different channel scenarios were considered for the propagation 
measurements: in-body to in-body (IB2IB), in-body to on-body 
(IB2OB), and in-body to off-body (IB2OFF). We provide for the 
first time path loss formulas for all these cases. 
 
Index Terms—body area network, implantable, in-body, path 
loss, propagation 
I. INTRODUCTION 
IRELESS technologies have revolutionized many 
aspects of modern life. Medicine and healthcare are not 
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the exceptions since multiple applications of radio 
technologies have had a beneficial impact on the way 
diagnosis and therapeutic procedures are performed [1]. In the 
same vein, the use of radio communications combined with 
biomedical sensors for the continuous monitoring of patients 
suffering from chronic diseases has gained significant 
attention as these solutions promise to lower the global 
expenditure in healthcare [2]-[4]. The interconnection of such 
wireless biomedical sensors to form a body area network 
(BAN) has been standardized in IEEE Std 802.15.6TM-2012 
[5], which specifies the physical (PHY) and medium access 
control (MAC) layers for communication on the surface, 
inside, or in the peripheral proximity of the human body. 
According to this standard, wearable BAN nodes can 
communicate in existing industrial, scientific, medical (ISM) 
bands as well as other frequency bands approved by national 
medical and/or regulatory authorities. These include the 
frequency band of 2360-2400 MHz [6], [7], which the United 
States Federal Communications Commission (FCC) has set 
aside for medical wearable sensors in order to complement the 
already crowded 2400-2483.5 MHz ISM band (simply 
referred to as the 2.4 GHz ISM band). However, as specified 
by IEEE Std 802.15.6TM-2012, in-body BAN nodes can 
communicate in the medical implant communication services 
(MICS) band only, i.e., 402-405 MHz [7]-[10]. Although the 
expected radio propagation losses through biological tissues in 
the MICS band may not be as high as within 2360-2400 MHz 
or 2400-2483.5 MHz, the maximal channel bandwidth of 300 
kHz allowed in the MICS band constrains the implantable 
devices to low data rate transmissions. Therefore, a number of 
other frequency bands have been considered for 
communication interfaces with medical implants and in-body 
electronic pills [11]-[13]. Wider channel bandwidths for novel 
and more sophisticated in-body wireless sensors and actuators 
may be exploited in frequency bands above 1 GHz at the 
expense of larger propagation losses. Despite this drawback, 
the feasibility of using the radio spectrum above 1 GHz for in-
body BAN applications should be investigated because 
utilizing higher frequencies can also reduce the physical 
dimensions of implantable antennas that may facilitate the 
further miniaturization of in-body BAN nodes. For instance, 
some of the 39 channels of 1 MHz bandwidth available in 
2360-2400 MHz could be employed for implant 
communications besides their intended application as on-body 
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radio interfaces; 79 similar channels are available in the 2.4 
GHz ISM band [7]. The idea of using the spectrum around 2.4 
GHz for communication with in-body BAN nodes has been 
proposed before and a variety of implantable antennas for this 
purpose have been designed, e.g., [14]-[24]. In addition, 
propagation losses of body implanted antennas were computed 
via numerical simulations with single- and three-layer tissue 
structures for the different ISM bands, namely 433 MHz, 915 
MHz, 2450 MHz, and 5800 MHz in [25]. However, no 
mathematical formulas for the path loss were provided in that 
study. On the other hand, numerical and experimental path 
loss investigations with ingested wireless implants in 402 
MHz, 868 MHz, and 2.4 GHz were presented in [26]. A log-
distance path loss formula as a function of the propagation 
distance, d, was introduced for the in-body to on-body channel 
scenario. In this model the path loss exponent, γ , which 
indicates the rate at which the path loss, PL, increases with d, 
had a value of 2.8 and 2.6 for data obtained from phantom 
measurements and numerical simulations at 2.4 GHz, 
respectively. Likewise, measurements in a phantom and 
numerical simulations of path loss for insulated dipole 
antennas in the ISM band at 2.457 GHz led to path loss 
formulas for the in-body to in-body channel scenario [27], 
[28]. In spite of all these research efforts, no comprehensive 
set of path loss models stemming from measurements or 
simulations in a single propagation medium for all the possible 
channel scenarios involving in-body BAN nodes has been 
reported in the literature. Therefore, to fill this gap we present 
a radio propagation study for 2360-2500 MHz, which covers 
the two frequency bands discussed above with potential use 
for implant communications. We performed channel 
measurements in a liquid phantom, i.e., a chemical solution 
specially formulated to reproduce the dielectric properties of 
human muscle tissues [29]. We considered three different 
channel scenarios: in-body to in-body (IB2IB), in-body to on-
body (IB2OB), and in-body to off-body (IB2OFF). We 
provide for the first time the path loss formulas for all these 
cases. 
The remainder of the paper is organized as follows: In 
Section II we describe the experimental setup and 
measurement methodology. Section III presents the path loss 
formulas for the different in-body channel scenarios. In 
Section IV we discuss the implications of our findings for the 
implementation of implant communications in 2.36-2.5 GHz. 
Finally, Section V summarizes our conclusions.  
II. EXPERIMENTAL SETUP AND MEASUREMENT 
METHODOLOGY 
A. In-Body Channel Scenarios 
The in-body channel scenarios that we considered herein 
combined the three possible locations of BAN nodes that the 
Channel Modeling Subgroup of IEEE Std 802.15.6TM-2012 
identified in [30]. Hence, these in-body channel scenarios can 
be described as: 
- IB2IB, a link between two implanted nodes. 
- IB2OB, a link between an implanted node and a node in 
direct contact with the skin or within 2 cm distance. 
- IB2OFF, a link between an implanted node and a node 
beyond 2 cm and up to 5 m from the body surface. 
Nevertheless, because of the limitations imposed by the 
physical size and construction of the phantom, the channel 
measurements were performed with the best possible 
approximation to the characteristics of each scenario. 
B. Experimental Setup 
The setup used for the IB2IB measurements is shown in 
Fig. 1, which consisted of a vector network analyzer, a cube-
shaped container, phantom aqueous solution, two insulated 
dipole antennas, and two coaxial cables. For the IB2OB and 
IB2OFF measurements one of the insulated dipoles was 
replaced with a free-space coax fed helical antenna with a 
dielectric support on a finite ground plane and six turns of 
copper wire. This free-space helical antenna exhibited a 
reflection coefficient of 1011 −<S  dB within 2.36-2.5 GHz 
and a gain of 7.7 dB at 2.4 GHz. The physical dimensions of 
these antennas are shown in Fig. 2. The antennas were 
connected to an Agilent TechnologiesTM ENA E5072A vector 
network analyzer (VNA), which had a maximal operation 
frequency of 8.5 GHz. Two coaxial cables of 1 meter in length 
with a maximal operation frequency of 12.4 GHz were used to 
connect the antennas to the VNA ports 1 and 2, respectively. 
The cables’ frequency response was subtracted from the 
channel measurements by performing a careful thru-
calibration of the VNA. Further details about some 








1 Vector Network Analyzer (VNA) 
2 StyrofoamTM Container 
3 Phantom Aqueous Solution 
4 Insulated Dipole Antenna 
5 Coaxial Cable  
Fig. 1.  Components of the measurement setup for the IB2IB channel scenario.  
Note that in this case the two implantable antennas were located along an 
imaginary diagonal line that divided the phantom in two triangular halves. 
This was done in order to obtain a larger transmission range. However, in the 
other two cases, i.e., IB2OB and IB2OFF, an implantable antenna and the 
helical antenna were located along an imaginary line that divided the phantom 
in two rectangular halves. 
 
 












Fig. 3.  Measured reflection coefficient of the insulated dipole antenna 
submerged in a liquid phantom with similar dielectric properties to muscle 
tissues. 
 
C. Phantom Aqueous Solution 
In order to approximate the propagation conditions of the 
human body within 2.36-2.5 GHz an aqueous solution of 
sucrose (C12H22O11) and sodium chloride (NaCl) was 
prepared. Reportedly, a solution with the following weight 
proportions: 59.5% of deionized water, 40% of sucrose, and 
0.5% of sodium chloride, approximates the dielectric 
characteristics of human muscle tissues at 2.45 GHz, i.e., 
relative permittivity 7.52=rε  and conductivity 73.1=σ  S/m 
[24]. However, slight changes in these dielectric parameters 
may occur because of ambient temperature variations. The 
prepared solution was poured into a cube-shaped container 
made of extruded polystyrene foam (StyrofoamTM) with wall 
thickness, thw , of 40 mm. The container’s size was 30×30×20 
cm3 (width×length×height) and the phantom solution occupied 
a volume of 22×22×16 cm3. Hereinafter we refer to this 
arrangement as “the phantom.” 
D. Insulated Dipole Antennas 
The insulated dipoles were designed with arms made of 
perfect electric conductor (PEC) material surrounded by an 
insulation made of polytetrafluoroethylene ( 07.2=rε  and 
0=σ  S/m) [27], [28]; in the physical implementation (Fig. 
2(a)), however, the arms were made of copper. These antennas 
were originally designed to resonate at 2.457 GHz when 
submerged in a phantom solution with 8.50=rε  and 
01.2=σ  S/m. However, through measurements of the 
reflection coefficient, i.e., 11S  parameter, we verified that the 
insulated dipoles covered properly the 2.36-2.5 GHz 
frequency band when submerged in our liquid phantom 
described above (Fig. 3). 
E. Measurement Methodology 
The measurements consisted of obtaining the forward 
channel gain in the frequency domain, i.e., ( )fS21 , within the 
band under analysis. Measurements were performed between 
2.36 GHz and 2.5 GHz with 20001=N  resolution points, 
thus the frequency resolution was 7=∆f  kHz. The VNA 
output power was set to 10 dBm and the noise floor was at –
110 dBm within a bandwidth 3IF =f kHz. All the measured 
data were recorded for processing and analysis in MatlabTM.  
Five snapshots of the channel were recorded to improve the 
signal-to-noise ratio (SNR). The path loss in dB was then 
calculated as ( ){ }fSPL 21mean−= . For each channel scenario, 
a discrete number of path loss points versus the corresponding 
distance separating the antennas, i.e., ( )idPL , were plotted and 
a continuous curve was fitted to the resulting scatter plot. The 
least square fitting method was then used to produce a path 
loss formula as a function of distance. 
III. PATH LOSS FORMULAS 
A. In-Body to In-Body (IB2IB) Channel Scenario 
In this scenario the two insulated dipoles were submerged in 
the phantom so that the center of each antenna was located at 
8 cm of depth aligned vis-à-vis in co-polarized mode. An 
antenna was fixed at a distance of 4 cm from the phantom’s 
internal edge whereas the second one was moved away from a 
starting distance 20=d  mm up to 140=d  mm in steps of 10 
mm (Fig. 4). 
The respective discrete scatter plots of ( )idPL  for the 
frequency bands of 2.36-2.4 GHz and 2.4-2.5 GHz are shown 
in Fig. 5. As seen, the difference in path loss between these 
two bands is negligible for all the considered distance points. 
Therefore, in order to produce a path loss formula the channel 
measurements were averaged over the entire frequency range 
of 2.36-2.5 GHz. The resulting scatter plot and fitted curve for 














Fig. 4.  Measurement setup for the IB2IB channel scenario. 
 
 
Fig. 5.  IB2IB scatter plots of path loss for 2.36-2.4 GHz and 2.4-2.5 GHz. 
 
 
Fig. 6.  IB2IB scatter plot and fitted curve of path loss for 2.36-2.5 GHz. 
 
In this case, the mathematical model (fitted curve) for the 
path loss in dB as a function of d in millimeters is a linear 
equation given as 
 
( ) dPLdPL α+= 0 ,                           (1) 
where 0PL  is an initial path loss value in dB observed in the 
limit when 0→d , and α  is a scaling factor. Here, 
9.110 =PL  dB and 7.0=α  dB/mm. This model is valid for 
14020 ≤≤ d  mm. For the interval 8020 ≤≤ d  mm and 
similar dielectric properties of the propagation medium, this 
model is in good agreement with the channel simulation and 
measurement results reported in [27], [28], where IB2IB path 
loss formulas valid for 805 ≤≤ d  mm were introduced. 
B. In-Body to On-Body (IB2OB) Channel Scenario 
In this scenario one insulated dipole was submerged in the 
phantom whereas the helical antenna (Fig. 2(b)) was facing it 
at the same height in direct contact with the external 
phantom’s wall. We denoted the distance from the insulated 
dipole to the phantom’s internal wall as ind . Notice that in this 
case the effective distance separating the two antennas in 
millimeters including the phantom’s wall thickness, thw , is 
 
thin wdd += .                               (2) 
 
However, we measured the path loss through the 40 mm thick 
StyrofoamTM wall and found it to be negligible, therefore one 
can assume that 
 
( ) ( )dPLdPL ≈in .                           (3) 
 
In a real-life IB2OB scenario where a wearable sensor is in 
direct contact with a patient’s skin, dd =in  and (3) may 
become ( ) ( )dPLdPL =in . Thus the helical antenna was kept 
fixed whereas ind  was varied by moving the dipole away in 
steps of 10 mm as shown in Fig. 7. The scatter plot and fitted 
curve as a function of ind  for 2.36-2.5 GHz are shown in Fig. 
8. A linear equation of the same form as (1) is a good model 
for the path loss in this case too, with 7.290 =PL  dB and 


















Fig. 8.  IB2OB scatter plot and fitted curve of path loss for 2.36-2.5 GHz. 
 
Notice that for the same distance value a larger path loss is 
observed in the IB2OB channel scenario when compared to 
IB2IB. This additional loss is a direct result of the impedance 
mismatch caused by the change of propagation medium along 
the propagation path [31]-[33].  
C. In-Body to Off-Body (IB2OFF) Channel Scenario 
The measurement setup for the IB2OFF scenario is similar 
to that of IB2OB, but here the insulated dipole was fixed at a 
distance ind  as in the previous scenario whereas the helical 
antenna was moved away from the phantom. We denoted the 
distance from the phantom’s internal wall to the helical 
antenna as offd  (Fig. 9). We considered three different fixed 
values for ind : 10 mm, 20 mm, and 30 mm. For each of these 
cases we put the helical antenna at multiple locations so that 
offd  varied from 40 mm to 540 mm. The resulting scatter plots 
and fitted curves as functions of offd  for 2.36-2.5 GHz are 
presented in Fig. 10. 
In this scenario, the fitted curve for the path loss in each 














dPLdPL ddd γ .             (4) 
 
where γ  is a path loss exponent and refd  is a reference 
distance equal to 1 mm. The subscript ind  in (4) indicates that 
the formula is valid for one of the three specific values of ind  
considered herein; the corresponding values of 0PL  and γ  for 
these three cases are given in Table I. 
 
TABLE I 
PATH LOSS PARAMETERS FOR IB2OFF CHANNEL SCENARIO 
 din=10 mm din=20 mm din=30 mm 
PL0 (dB) 22.5 26.3 32.4 















Fig. 9.  Measurement setup for the IB2OFF channel scenario. 
 
 
Fig. 10.  IB2OFF scatter plots and fitted curves of path loss for 2.36-2.5 GHz. 
 
As expected, in this scenario the wave propagation through 
the aqueous phantom solution was the largest contributor to 
the total path loss along d. This can be observed by comparing 
Figs. 8 and 10, where it is evident that the rate at which the 
path loss increases with distance is significantly lower in the 
air. As hinted in [30], the path loss in the IB2OFF channel 
scenario can be approximated by considering a combination of 
IB2OB and indoor path loss models; when no surrounding 
objects and obstacles are present, then simply the free-space 
loss can be added to the IB2OB path loss.   
IV. DISCUSSION 
The set of path loss formulas presented above are aimed to 
provide some insight into the behavior of the different in-body 
channel scenarios to assist the biomedical engineer in the early 
stage of the design of wireless implantable sensors. It is clear 
that these path loss models are antenna-dependent as the vast 
majority of other BAN propagation models proposed in the 
literature. As the wavelength of the propagating signal in the 
phantom aqueous solution is 17=λ mm, some of the 
measurements were inevitably performed within the reactive 
near-field of each dipole antenna, the boundary of which is 
 
36=R mm. However, implantable and free-space antennas 
with 1011 −<S  dB were used in all the channel scenarios to 
try to counter as much as possible the antenna effects on the 
path loss. Although channel measurements in a homogeneous 
propagation medium like an aqueous phantom solution do not 
fully capture the effects of propagation through 
inhomogeneous multilayer structures like the human body, 
they provide practical rules of thumb to assess the feasibility 
of establishing reliable communications for some implantable 
biomedical applications within 2.36-2.5 GHz.   
For instance, consider the ultralow power radio system for 
BAN applications designed in [34], which can operate in 2.36-
2.4 GHz and the 2.4 GHz ISM band. The transmitter (Tx) of 
this system utilizes a basic on-off keying (OOK) modulation 
scheme with 0 dBm peak power. Including the Tx baseband, 
the Tx power consumption is 4.243 mW when transmitting a 
logical “1” and 0.919 mW for a logical “0.” The receiver (Rx) 
front end achieves a sensitivity of −75 dBm at 5 Mbps and 
−78 dBm at 3 Mbps. Therefore, if this radio system is 
equipped with properly matched implantable/on-body 
antennas accordingly, the maximal transmission range that 
may be attained for the different in-body scenarios can be 
estimated with the path loss formulas we provided. 
From (1) it follows that for IB2IB the maximal transmission 
range of this BAN system is 90 mm and 94 mm for 5 Mbps 
and 3 Mbps, respectively. These transmission ranges are 
suitable for some communication applications in the thoracic 
cavity, e.g., wireless sensing for a subcutaneous implantable 
cardioverter-defibrillator (s-ICD) [35], [36]. An implanted 
cardiovascular pressure monitor integrated with a medical 
stent [37] could send an alert signal on a wireless interface 
within 2360-2483.5 MHz to the s-ICD in order to deliver 
transthoracic shocks when ventricular tachyarrhythmias are 
detected. 
Similarly, for IB2OB the maximal transmission range is 75 
mm and 80 mm for 5 Mbps and 3 Mbps, respectively. These 
transmission ranges represent the maximal implantation 
depths from the skin for the wireless sensors. Hence, 
applications like the insertable loop recorder (ILR) [38] and 
continuous glucose monitoring (CGM) systems [39] could 
also benefit from smaller antenna sizes by using radio 
interfaces within 2360-2483.5 MHz. Since these applications 
utilize a subcutaneous wireless sensor, i.e., a sensor implanted 
just under the patient’s skin, the transmission range could 
likely be extended to IB2OFF for communication with a hand-
held patient assistant unit to display, analyze, and record the 
physiological data. On the other hand, the above transmission 
ranges for IB2OB within 2360-2483.5 MHz may not fulfill the 
transmission range requirements for some electronic pill 
applications like the wireless capsule endoscope (WCE) [11]. 
In this biomedical application the transmission range varies 
widely as the WCE travels inside the gastrointestinal (GI) tract 
transmitting images to a belt receiver/recorder that the patient 
has to wear during the entire endoscopic procedure 
(approximately 8 hours). An average transmission range of 
200 mm is typically required for a WCE procedure, but up to 
500 mm may be needed in some cases. Therefore, practical 
solutions like the use of a matching layer and spatial diversity 
reception that have been studied in the context of ultra 
wideband (UWB) WCE [40]-[42] should be also investigated 
for 2360-2483.5 MHz. 
Nevertheless, the designer of an implantable 
communication link using our path loss models has to take 
into account the fact that miniaturized implantable antennas 
may not be so well matched to the medium as the dipoles used 
in our measurements. Implantable antenna mismatch and other 
varying factors like the different thicknesses of fat layer of the 
patients require the addition of a link budget margin to the 
path loss calculation. The value of such margin is generally 
determined based on practical prototype tests. 
V. CONCLUSIONS 
We have presented a collection of path loss models for 
2.36-2.5 GHz derived from measurements in a liquid phantom 
that reproduced the dielectric characteristics of human muscle 
tissues. These results provide useful insight into the behavior 
of the different radio channel scenarios for implant 
communications. However, the fact that the measurements 
were performed using a homogeneous propagation medium 
leaves some room for improvement. Therefore, our future 
work considers the performance of in-vivo channel 
measurements in an animal subject. Such a measurement 
campaign will allow capturing the effects of blood circulation, 
respiration, and temperature gradients on the path loss for the 
different in-body channel scenarios, which are not properly 
modeled in most cases; even numerical simulations using 
digital anatomical models often fail to capture these effects. 
From the experience gained after multiple in-vivo tests of 
implantable radio transceivers at the Intervention Centre, Oslo 
University Hospital [43], [44], we have concluded that 
channel measurements on a living porcine subject can produce 
path loss formulas that fairly approximate the propagation 
characteristics in the human torso. It will be necessary, 
however, to perform the measurements using various types of 
antennas with significantly variable sizes in order to fully 
validate the parameters of the formulas presented in this paper.  
Our current path loss models for the different in-body 
channel scenarios indicate that radio interfaces within 2.36-2.5 
GHz are feasible for some implantable biomedical sensors. 
The use of these frequency bands can promote further 
miniaturization of the antennas, a very important design aspect 
for biomedical implants. At the same time, wider channel 
bandwidths will be available for the transmission of larger 
amounts of physiological data. The design of radio 
transceivers for implants operating within 2.36-2.5 GHz will 
be a part of our future research activities too. Optimal 
transceiver design, however, calls for more accurate 
characterization of the different in-body radio channel 
scenarios. Hence, this study could contribute to spark further 
research interest toward the exploitation of this portion of the 
spectrum for implant communications. 
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